小剂量利伐沙班用于动脉粥样硬化性心血管疾病的药物利用评价标准构建与应用

打开文本图片集

中图分类号R972 文献标志码A 文章编号 1001-0408（2025）17-2176-06

DOI 10.6039/j.issn.1001-0408.2025.17.16

Constructionand application of thecriteria for drug utilization evaluationof low-dose rivaroxaban in atheroscleroticcardiovasculardisease

WU Liang'，WANG Wei²， XU Yanghui'， ZHU B01 ，KE Yijun’（1. Dept. of Pharmaceutical Management，Anqing Municipal Hospital，Anhui Anqing 246003，China;2.Dept.of Gastroenterology，Anqing Municipal Hospital， Anhui Anqing 246003， China）

ABSTRACTOBJECTIVE Toconstruct and aply drug utlization evaluation（DUE）criteria for low-doserivaroxaban in atheroscleroticcardiovasculardisease（ASCVD）basedonthedual pathwayinhibition（DPI）antithrombotic therapyscheme，to promote clinical rational drug use.METHoDS Based on the instructions and relevant guidelines of low-dose rivaroxaban （ 2.5mg ， bid），theDelphi method wasusedtoestablishtheDUEcriteriaforlow-doserivaroxabanusedinASCVD.Weightedtechniquefor orderpreferencebysimilaritytoanidealsolutionmethodwasusedtodeterminetherelativeweightsofeachevaluationindex，and therationalityofthefiling medicalrecordsofdischarged patientsusing low-doserivaroxabanforASCVDatAnqing Municipal HospitalfromFebruary2024toJanuary2O25was evaluated.RESULTSTheestablishedDUEciteria included3primaryindicators （medication indications，medicationprocess，medicationresults）and11secondaryindicators（suchasindications， contraindications，etc.）.Thehigherweightedsecondaryindicatorsbeingcontraindications（0.1179）andindications（O.111）.A total of 265 medical records were included for evaluation.The evaluation results showed that 192 cases （ 72.45% ）hadreasonable medical records，69 cases （26.04% ）had basic reasonable medical records，and 4 cases（ 1.51% ）had unreasonable medical records; unreasonabletypesmainlyincludedinappropriatecombinationtherapy，inappropriateusageanddosage，inappropriatepostmedicationmonitoring，and inappopriatedrugswitching，etc.CONCLUSIONSThisstudyestablishesaDUEciteriaforlow-dose rivaroxaban inASCVDbasedontheDPIantithrombotictreatmentregimen，andtheevaluationresultsareintuitive，reliable，and quantifiable.Theuseoflow-doserivaroxabaninASCVDpatients inourhospital isrelativelyreasonable，butfurther management needs to be strengthened.

KEYWORDSrivaroxaban；dualpathwayinhibitionantithrombotictreatmentregimen；atheroscleroticcardiovasculardisease; drug utilization evaluation

随着人口老龄化的加速及心血管危险因素的流行，动脉粥样硬化性心血管疾病（atheroscleroticcardiovascu-lardiseases，ASCVD）在世界范围内具有较高的发病率和死亡率1]。（剩余12512字）